Wall Street analyst estimates for Natera, Inc. (NTRA): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations.
Consensus price target
$386.00 (-4 % vs price $403.95)
between $245.00 and $500.00 · 18 targets published in the last quarter
Closing price, Oct 29
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $2.9B | $2.9B – $2.9B | $-1.45 | 12 |
| 2027E | $3.5B | $3.4B – $3.6B | $-0.34 | 12 |
| 2028E | $4.3B | $4.0B – $4.8B | $1.35 | 16 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 25 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 28 |
| Avg rating (−2 sell to +2 buy) | 0.89 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.28 | ||
| 2026-08-06 | $-0.47 | $-0.49 | +4.8% |
| 2026-05-07 | $-0.56 | $-0.54 | -3.3% |
| 2026-02-26 | $0.35 | $-0.51 | +168.4% |
| 2025-11-06 | $-0.64 | $-0.39 | -65.9% |
| 2025-08-07 | $-0.74 | $-0.62 | -20.2% |
| 2025-05-08 | $-0.50 | $-0.64 | +21.9% |
| 2025-02-27 | $-0.41 | $-0.38 | -7.6% |
Valuation Ratios
| Price / Book | 34.30 |
| EV / EBITDA | -346.90 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $217.1M | $210.9M | $257.7M | $302.3M | $391.0M | $625.5M | $820.2M | $1.08B | $1.70B | $2.31B |
| Cost of Revenue | $135.6M | $139.6M | $166.1M | $175.5M | $203.6M | $318.4M | $456.3M | $589.8M | $673.8M | $810.6M |
| Gross Profit | $81.5M | $71.3M | $91.6M | $126.9M | $187.4M | $307.1M | $364.0M | $492.7M | $1.02B | $1.50B |
| Research & Development | $41.9M | $50.1M | $51.4M | $51.4M | $100.0M | $264.2M | $316.4M | $320.7M | $404.1M | $624.1M |
| Selling, General & Admin | $136.1M | $155.3M | $154.9M | $206.2M | $303.6M | $511.0M | $588.6M | $618.3M | $841.3M | $1.18B |
| Operating Expenses | $178.0M | $205.4M | $206.2M | $243.1M | $403.7M | $775.2M | $905.0M | $939.0M | $1.25B | $1.81B |
| Operating Income | -$96.5M | -$134.0M | -$114.6M | -$116.3M | -$216.3M | -$468.2M | -$541.0M | -$446.2M | -$222.3M | -$309.9M |
| EBITDA | -$93.4M | -$125.8M | -$107.1M | -$104.4M | -$205.9M | -$451.5M | -$520.8M | -$397.8M | -$148.1M | -$220.5M |
| Interest Expense | $533,000 | $4.2M | $10.5M | $10.7M | $15.1M | $8.3M | $9.3M | $12.6M | $10.7M | $4.1M |
| Pre-tax Income | -$95.6M | -$135.9M | -$127.8M | -$122.8M | -$229.6M | -$471.1M | -$546.8M | -$434.5M | -$189.7M | -$268.1M |
| Income Tax | $142,000 | $454,000 | $321,000 | $2.0M | $98,000 | $618,000 | $978,000 | $271,000 | $695,000 | -$59.9M |
| Net Income | -$95.8M | -$136.3M | -$128.2M | -$124.8M | -$229.7M | -$471.7M | -$547.8M | -$434.8M | -$190.4M | -$208.2M |
| EPS | $-1.86 | $-2.56 | $-2.22 | $-1.79 | $-2.84 | $-5.21 | $-5.57 | $-3.78 | $-1.53 | $-1.52 |
| EPS (Diluted) | $-1.86 | $-2.54 | $-2.22 | $-1.79 | $-2.84 | $-5.21 | $-5.57 | $-3.78 | $-1.53 | $-1.52 |
| Shares Outstanding (Diluted) | 51.6 M | 53.6 M | 57.8 M | 69.6 M | 81.0 M | 90.6 M | 98.4 M | 115.0 M | 124.7 M | 136.7 M |
Price
| Price | $403.95 (closing price, October 29, 2026) |
| Market Cap | $58.2B |
| Exchange | NASDAQ |
| Country | US |
Related companies: BLLN · VCYT · TMO · 0R0H.L · DHR · 0R2B.L · A · 0HAV.L
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of NTRA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks